Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Lund January 9, 2017 - Active Biotech AB (Nasdag Stockholm: ACTI) announces today that the European Patent Office has decided to grant Active Biotech's patent application covering tasquinimod for use in the treatment of multiple myeloma. The patent will be granted as European Patent No. 3041472 on February 1, 2017 and has a duration lasting until 2035.
For further information, please contact:
| Tomas Leanderson, President & CEO Tel: +46 46 19 20 95 Hans Kolam, CFO Tel: +46 46 19 20 44 | Active Biotech AB (Org.nr 556223-9227) Box 724, 220 07 Lund Tel: +46 46 19 20 00 |
About tasquinimod
Tasquinimod is an immunomodulatory, anti-metastatic and anti-angiogenic compound that affects the tumor's ability to grow and spread. The development of tasquinimod has previously been focused on the treatment of prostate cancer with clinical proof of concept and a good safety profile shown in Phase 2 and 3 studies. Tasquinimod's mechanism of action is broadly applicable as anti-tumor treatment and very good results have been achieved in models for multiple myeloma, a blood cancer with a high medical need. Active Biotech is seeking a partner for the continued development of tasquinimod in multiple myeloma.
Active Biotech AB (publ) (Nasdag Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in pivotal Phase 3 development for the treatment of relapsing remitting multiple sclerosis. Also, laquinimod is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.
This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13.00 pm CET on January 9, 2017.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/54311b72-eb9f-4451-ac41-4c9d3b892f19
